References
- Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36:2271-9
- Ali MK, Bullard KM, Gregg EW. Achievement of goals in U.S. Diabetes Care, 1999–2010. N Engl J Med 2013;369:287-8
- Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014
- American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 2015;38(1 Suppl):S1-93
- American Association of Clinical Endocrinologists and American College of Endocrinology. Comprehensive diabetes management algorithm. Endocr Pract 2015;21(1 Suppl):S1-87
- Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013;5:6
- Bennett WL, Wilson LM, Bolen S, et al. Oral diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
- Victoza® [package insert]. Plainsboro, NJ: Novo Nordisk; 2010.
- Perry CM. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs 2011;71:2347-73
- Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta–analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14:77-82
- Lee WC, Dekoven M, Bouchard J, et al. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. Diabetes Obes Metab 2014;16:819-26
- Chitnis AS, Ganz ML, Benjamin N, et al. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther 2014;31:986-99
- Chitnis AS, Ganz ML, Hammer M, et al. Real-world clinical effectiveness of liraglutide in individuals 65 years and older with type 2 diabetes in the United States. J Diabetes Metab 2014;5:1-6
- Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm 2013;19:237-46
- DeKoven M, Lee WC, Bouchard J, et al. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther 2014;31:202-16
- Li Q, Chitnis A, Hammer M, et al. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther 2014;5:579-90
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(1 Suppl):S14-80
- Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther 2013;15:776-85
- Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009;121:5-15
- Gallwitz B, Vaag A, Falahati A, et al. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010;64:267-76
- Garber A, Mathews D, Zinman B, et al. The effect of disease stage, indicated by number of previous oral antidiabetic agents, on the response to liraglutide in type 2 diabetes. Diabetes 2011;60(1 Suppl):A265
- Heymann A, Maor Y, Goldstein I, et al. Efficacy of liraglutide in a real-life cohort. Diabetes Ther 2014;5:193-206
- Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
- Mezquita Raya P, Reyes Garcia R. Is treatment with liraglutide efficient? Endocrinol Nutr 2014;61:202-8